HOME
ABOUT
About US
Corporate culture
Company honor
Development course
PRODUCT
Drugs in the field of tumor-re
Drugs in other fields
Health care products
R&d innovation
R&d pipeline
R&d progress
Patient recruitment
NEWS
Company dynamics
Trade news
Academic exchanges
INVESTOR
Latest announcement
H&R
Job development
Talent recruitment
CONTACT
Notice
EN
CN
HOME
ABOUT
About US
Corporate culture
Company honor
Development course
PRODUCT
Drugs in the field of tumor-re
Drugs in other fields
Health care products
R&d innovation
R&d pipeline
R&d progress
Patient recruitment
NEWS
Company dynamics
Trade news
Academic exchanges
INVESTOR
INVESTOR
Latest announcement
H&R
Job development
Talent recruitment
CONTACT
Notice
Shengbai Oral Liquid (Mixture) was included in the "2018 Clinical Pathway Therapeutic Drug Interpretation: Blood Diseases Volume" for the treatment of Chinese patent medicines for blood diseases
2018-11-22
PREV
Shengbai Oral Liquid (Mixture) was included in the "2018 Clinical Pathway Therapeutic Drug Interpretation: Tumor Disease Volume" anti-tumor Chinese patent medicine
NEXT
Shengbai Oral Liquid: Progress and Prospect of Integrated Traditional Chinese and Western Medicine in Clinical Oncology
Hot news
What kind of treatment is needed fo...
How much do you know about leukopen...
Should leukopenia be discontinued i...
Meta-analysis of the efficacy of S...
How to deal with leukopenia after c...
Shengbai Oral Liquid: Progress a...
Should I stop chemotherapy if I h...
Polysaccharides were included in th...